Compare · ILMN vs OSCR
ILMN vs OSCR
Side-by-side comparison of Illumina Inc. (ILMN) and Oscar Health Inc. (OSCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ILMN and OSCR operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $28.93B, about 3.1x OSCR ($9.37B).
- Over the past year, ILMN is up 96.7% and OSCR is up 108.2% - OSCR leads by 11.5 points.
- ILMN has been more active in the news (10 items in the past 4 weeks vs 9 for OSCR).
- Both have 25 recent analyst ratings on file.
- Company
- Illumina Inc.
- Oscar Health Inc.
- Price
- $191.24+0.57%
- $31.07-1.71%
- Market cap
- $28.93B
- $9.37B
- 1M return
- +15.15%
- +7.45%
- 1Y return
- +96.69%
- +108.21%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2000
- 2021
- News (4w)
- 10
- 9
- Recent ratings
- 25
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Oscar Health Inc.
Oscar Health, Inc. provides health insurance products and services in the United States. The company offers Individual & Family, Small Group, and Medicare Advantage plans, as well as +Oscar, a full stack technology platform. It also provides reinsurance products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was founded in 2012 and is headquartered in New York, New York.
Latest ILMN
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Latest OSCR
- SEC Form 4 filed by Director Gassen William
- SEC Form 4 filed by Director Sankaran Sid
- SEC Form 4 filed by Director Plouffe David
- Oscar Health, Inc. 2026 Second Quarter Earnings Conference Call
- Director Schlosser Mario converted options into 47,500 shares and sold $1,484,014 worth of shares (47,500 units at $31.24) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Bertolini Mark T sold $35,767,322 worth of shares (1,238,996 units at $28.87) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 7,751,570 units (SEC Form 4) (for withholding tax)
- Chief Executive Officer Bertolini Mark T sold $34,912,078 worth of shares (1,206,310 units at $28.94) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 8,990,566 units (SEC Form 4) to cover withholding tax
- Director Schlosser Mario converted options into 1,027,500 shares and sold $30,183,413 worth of shares (1,027,500 units at $29.38) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Oscar Health Inc.
- Oscar Health upgraded by Barclays with a new price target